← Back to Search

Drug-Checking Services + PrEP for HIV Prevention (SCOPE Trial)

N/A

Recruiting

Led By Susan Sherman, PhD

Research Sponsored by Johns Hopkins Bloomberg School of Public Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured at 6, 12, 18 months

Awards & highlights

SCOPE Trial Summary

This trial will provide drug-checking services and PrEP to people who use drugs in Baltimore to reduce overdose and HIV.

Who is the study for?

This trial is for adults over 18 in Baltimore who use stimulants or opioids, have had unprotected sex recently, are HIV negative, and may have had an STI. They must be willing to undergo drug screening, HIV and STI testing. Those too impaired or unable to consent can't join.Check my eligibility

What is being tested?

The SCOPE study is evaluating a program that combines drug-checking services with PrEP (a medication preventing HIV) for people using drugs. The goal is to reduce both overdoses and new HIV infections among participants.See study design

What are the potential side effects?

While the description doesn't list specific side effects, PrEP can sometimes cause nausea, headaches, stomach pain, weight loss and fatigue. Drug-checking services themselves do not involve taking medications but rather assessing substances' safety.

SCOPE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured at 6, 12, 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured at 6, 12, 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured at 6, 12, 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in PrEP uptake as assessed by study team instrument items

Current PrEP status as assessed by study team instrument items

Secondary outcome measures

Change in HIV Risk Behaviors as assessed by study team instrument items

SCOPE Trial Design

1Treatment groups

Experimental Treatment

Group I: SCOPE CohortExperimental Treatment1 Intervention

A cohort of PWUD (N=600) living in Baltimore. We will follow-up with participants every 6 months (for 18 months) in five recruitment zones throughout Baltimore (n=120/zone). The five recruitment zones will overlap the intervention sites. There will be 4 study visits (baseline, 6 months, 12 months, 18 months) total for participants.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

National Institutes of Health (NIH)NIH

2,701 Previous Clinical Trials

7,506,250 Total Patients Enrolled

National Institute on Drug Abuse (NIDA)NIH

2,470 Previous Clinical Trials

2,619,131 Total Patients Enrolled

Baltimore City Health DepartmentOTHER

7 Previous Clinical Trials

18,400 Total Patients Enrolled

Media Library

SCOPE Cohort Clinical Trial Eligibility Overview. Trial Name: NCT05977881 — N/A

Human Immunodeficiency Virus Infection Research Study Groups: SCOPE Cohort

Human Immunodeficiency Virus Infection Clinical Trial 2023: SCOPE Cohort Highlights & Side Effects. Trial Name: NCT05977881 — N/A

SCOPE Cohort 2023 Treatment Timeline for Medical Study. Trial Name: NCT05977881 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor still open for recruitment?

"As per clinicaltrials.gov, this investigation is actively recruiting participants and has been continuously updated since its posting on July 28th 2023. The most recent changes were implemented on August 3rd 2023."

Answered by AI

How many people are involved in this clinical research project?

"Indeed, the information hosted on clinicaltrials.gov validates that this trial is actively seeking participants. It was initially posted on July 28th 2023 and last updated August 3rd of the same year. Aspiring candidates need to go through one site with a total enrollment goal of 600 patients."

Answered by AI

Recent research and studies

MMWR. Morbidity and Mortality Weekly ReportJournal

Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014

Rudd, Rose A., Noah Aleshire, Jon E. Zibbell, and R. Matthew Gladden. 2016. “Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014”. MMWR. Morbidity and Mortality Weekly Report. Centers for Disease Control MMWR Office. doi:10.15585/mmwr.mm6450a3.

clinicaltrials.govStudy

Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study

2023. "Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05977881.